India looks to diplomats to salvage R&D rep; Parexel updates its eClinical offering;

> Ongoing global scrutiny tied to Indian CROs and CMOs is hampering the nation's effort to become a go-to outlet for biopharma R&D, and now the country's diplomats are working to improve the domestic industry's reputation around the world. Story

> Parexel ($PRXL) has updated its eClinical technology, Perceptive MyTrials, to include a mobile-friendly platform that allows sponsors to monitor predictive data analytics for multiple studies at the same time. More

> An independent lab network has bought into the CRO industry, paying an undisclosed sum for Analytical Bio-Chemistry Laboratories. News

Suggested Articles

Major CRO player Pharmaceutical Product Development is set to go back on the public markets after announcing its IPO plans.

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.